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Background: Accrual to Cancer Control and Supportive Care (CCL) studies can be challenging. Our objective was
to identify facilitators and perceived barriers to successful Children’s Oncology Group (COG) CCL accrual from the
clinical research associate (CRA) perspective.
Methods: A survey was developed that focused on the following features from the institutional perspective:
(1) Components of successful accrual; (2) Barriers to accrual; (3) Institutional changes that could enhance accrual; and
(4) How COG could facilitate accrual. The survey was distributed to the lead CRA at each COG site with at least 2 CCL
accruals within the previous year. The written responses were classified into themes and sub-themes.
Results: 57 sites in the United States (n = 52) and Canada (n = 5) were contacted; 34 (60%) responded. The four
major themes were: (1) Staff presence and dynamics; (2) Logistics including adequate numbers of eligible patients;
(3) Interests and priorities; and (4) Resources. Suggestions for improvement began at the study design/conception
stage, and included ongoing training/support and increased reimbursement or credit for successful CCL enrollment.
Conclusions: The comments resulted in suggestions to facilitate CCL trials in the future. Soliciting input from key
team members in the clinical trials process is important to maximizing accrual rates.
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Children with cancer have experienced dramatic im-
provements in survival and about 80% of children are
now expected to survive at least 5 years [1]. Much of
this improvement can be attributed to the formation of
multi-institutional co-operative groups that facilitate
conduct of trials for these relatively rare diseases, and
the widespread acceptance of clinical trials among pediatric
oncologists [2]. Because of this improvement in survival,
more attention has been focused on recognition, manage-
ment and prevention of short- and long-term treatment-
related toxicity [3].
Almost all children with cancer in the United States
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reproduction in any medium, provided the orChildren’s Oncology Group (COG), the largest cancer
group focused exclusively on children and adolescents
[4]. The COG Cancer Control and Supportive Care
(CCL) Committee develops clinical trials focused on the
prevention and treatment of acute toxicities in children
with cancer [5]. CCL studies are also important in terms
of the prevention or minimization of potential late effects
of therapy. Outcomes of primary interest have included
infection, neurocognition and other neurotoxicities, nutri-
tional status, chemotherapy-induced nausea and vomiting,
and quality of life. CCL is supported by the Division of
Cancer Prevention at the National Cancer Institute [6].
Timely accrual to studies is important. As is the case
with therapeutic studies, CCL trials must be completed
in a timely fashion so that the results are relevant
and so that patients can benefit from the knowledge
derived from these trials. Failure to accrue to these
clinical trials results in major financial, resource, scientific
and lost opportunity costs. Accrual may be particularlyl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prioritized lower than therapeutic studies by clinicians
and institutions [7].
Given the importance of timely accrual and the poten-
tial for challenges with the activation of, and accrual to
CCL trials [8], we sought to identify modifiable barriers
to CCL enrollments in order to develop strategies to im-
prove accrual. While the roles of the physician, institu-
tion and patient have been highlighted as important in
terms of successful trial conduct [9], others have empha-
sized the role of institutional clinical trials coordinators
or clinical research associates (CRAs) [10]. More specif-
ically, the opinions of CRAs may be particularly import-
ant since they are one of the key personnel responsible
for accrual to clinical trials. Further, they are one of the
only vested individuals who do not have patient care re-
sponsibilities and thus, are likely to have a unique and
important perspective. Our objective was to identify
facilitators and perceived barriers to successful CCL
accrual from the CRA perspective.
Methods
There are approximately 200 institutions that participate
in COG clinical trials. A survey was developed by the
CCL Committee CRA representative (DV). The survey
was distributed to the lead CRA at each COG site
with at least 2 COG CCL accruals within the previous
year. In the case of non-response, the survey was re-
distributed one additional time. The distributions oc-
curred in February and March 2013. Because this survey
was developed to improve CCL accrual among COG in-
stitutions (in other words, this project was considered a
quality improvement project), Institutional Review Board
oversight was not required. All CCL trials are performed
in compliance with the Helsinki Declaration, and all of
the CCL trials described in this manuscript were ap-
proved by the National Cancer Institute's Central Institu-
tional Review Board.
The survey consisted of four open-ended questions:
(1) What do you feel are the components of successful
accrual at your institution? (2) What are the barriers to
accrual at your institution? (3) If you could change one
thing at your institution to increase accrual to CCL trials
what would it be? and (4) How can we (CCL) as a com-
mittee contribute to successful accrual at your institu-
tion? For question (4), the institutional lead CRA was
asked to discuss this issue with his/her principal investi-
gator and to provide a response that reflected that insti-
tution’s perspective.
The written responses were collated and catego-
rized using thematic analysis by two investigators (TH
and LS) in an iterative fashion [11,12]. Sample quotes
were identified to support themes and sub-themes. A
third investigator (DV) reviewed the final categorization.The number of comments identified within each them
and sub-theme was tabulated.
Results
Fifty seven COG sites, located in the United States
(n = 52) and Canada (n = 5), had enrolled at least 2 par-
ticipants on CCL studies between December 1, 2011 to
November 30, 2012. At the time of survey dissemination,
there were 8 CCL studies that were either open or had re-
cently closed to patient accrual within the previous year
(Additional file 1: Table S1). The mean number of accruals
to CCL studies from the 57 sites was 6.2 (range 2 to 32).
The response rate from the 57 sites was 34 (60%).
Tables 1 and 2 illustrate the themes, sub-themes and
example quotations related to the facilitators and barriers
identified at institutions. Comments suggesting what could
be done by institutions to improve accrual recapitulated
the contents of Tables 1 and 2 and therefore, a separate
table is not shown. Table 3 demonstrates suggestions for
how COG and the CCL Committee could facilitate CCL
accruals. Figure 1 illustrates an overview of themes and
sub-themes of barriers and facilitators to accrual to CCL
studies.
In general, there were four major themes in each of
the areas: (1) Staff presence and dynamics; (2) Logistics
including adequate numbers of eligible patients; (3) In-
stitutional interests and priorities; and (4) Resources.
Facilitators and barriers within each theme tended to
identify the same issue from different perspectives. For
example, under “staff presence and dynamics”, the main
facilitators were presence of a CCL champion, a dedi-
cated team for CCL studies, and communication and
awareness of CCL studies within that team. Involvement
of physicians was highlighted as particularly helpful,
especially in regard to obtaining consent for some types
of studies such as studies requiring an investigational
new drug application. Conversely, lack of a team ap-
proach, limited time, lack of communication and lack of
awareness were identified as major barriers to patient
enrollment. More specifically, lack of awareness focused
on the lack of knowledge about open CCL trials and
which patients would be eligible for these trials.
"If we have a specific person who is "championing" the
protocol we have more accrual to the protocol."
“Logistics” focused on whether there were adequate
numbers of eligible patients available; CRAs highlighted
the importance of wide or non-restrictive eligibility cri-
teria. In terms of study design, CRAs stressed the need
for studies that are feasible and practical with minimal
data collection requirements. CRAs reported that enroll-
ment onto CCL studies may be enhanced where other
competing studies can be minimized, such as after the
Table 1 Factors related to successful accrual to cancer control studies at institutions
Themes and sub-themes (number of times mentioned) Example quotations
Staff presence and dynamics (35)
Dedicated team/staff (11) "Accrual has proven to be most successful when a CRA/Research Nurse has been
highly involved."
Staff awareness of CCL studies (9) "Awareness (includes CRAs, staff physicians, nurses, fellows) - we feel that very few
individuals are aware of these studies." "Weekly COG meetings with research nurse,
CRAs and PI; we all know where studies stand, cuts down on emails between each
other; helps prioritize studies."
Team communication (6) "A more clear system of communication when potential patients are identified."
"It's basically a team approach."
Physician consent/support (6) "Having a physician's support in identifying and consenting patients is a very
important component for accrual."
Presence of a CCL champion (3) "If we have a specific person who is "championing" the protocol we have more
accrual to the protocol."
Logistics including adequate numbers of eligible patients (7)
Ability to identify eligible patients (4) "Part of successful accrual is being organized in tracking and approaching all
eligible patients."
Eligible/willing patients (2) "Patient willingness."
Timing of approach (1) "Timing of consent discussion (not at diagnosis as families are overwhelmed
with information)."
Interests and priorities (11)
Patient potential benefit (4) "Protocols that have potential patient benefit or have therapeutic intent (ACCL0933)
are prioritized over other CCL studies."
Division/department interest/support (3) "Our institutional stance is that CCL trials need to be broadly supported and
embraced by the COG voting body,"
Prioritization of CCL studies at institution (2) "Our division as a whole being interested and supportive of COG studies,"
No competing treatments (2) "If [competing treatments] were to open that could affect the accrual rate for the
CCL studies."
Resources (5)
Funding and resources (5) "CCL trials need to be (…) supported with adequate funding."
Abbreviation: CCL, Cancer Control and Supportive Care; COG, Children’s Oncology Group; CRA, Clinical research associate; PI, Principal investigator.
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disease-specific therapeutic studies available.
“Timing of consent discussion (not at diagnosis as
families are overwhelmed with information)."
In terms of “interests and priorities”, a preference was
indicated for interventional studies with potential thera-
peutic benefit for patients, over those that are purely
descriptive. In contrast, concern about side effects of CCL
pharmaceutical interventions was raised. The possibility
for monetary patient incentives was also mentioned.
“Protocols that have potential patient benefit or have
therapeutic intent (ACCL0933) are prioritized over
other CCL studies."
A large number of comments were generated in terms
of “resources”. On multiple occasions, greater per-case
reimbursement and reimbursement for study procedureswere emphasized. A request for central CRA resources to
manage some of the regulatory requirements was identi-
fied. In addition, a suggestion that CCL accruals “count”
similar to therapeutic accruals in terms of institutional
stance within COG was made. Finally, the importance of
information provision and ongoing education and train-
ing was noted.
"CCL trials need to be (…) supported with adequate
funding."
Discussion
We identified that four themes important for patient ac-
crual on COG CCL studies are staff, logistics, interests/
priorities and resources. The CRAs generated concrete
and reasonable suggestions to facilitate accrual to CCL
trials in the future. Such approaches begin at the study
design/conception stage and include ongoing training/
support and increased reimbursement or credit for suc-
cessful CCL enrollment.
Table 2 Barriers to cancer control trial accrual at institutions
Themes and sub-themes (number of times mentioned) Example quotations
Staff presence and dynamics (29)
Insufficient staff (16) "No CRA manpower to dedicate to data collection and study coordination."
Insufficient time (7) "The most pressing problem is time - not enough time to get all of the
protocols through the IRB and not enough to complete data."
"Sometimes identified patients end up not going on study due to the lack
of time for consenting by staff physicians/fellows/NPs in a timely manner."
Lack of communication (4) "(Need) good communication between the research team and the
clinical team."
Lack of awareness (2) "Lack of knowledge by the clinical staff of available and currently open
COG studies."
Logistics including adequate numbers of eligible patients (26)
Eligibility criteria too restrictive (13) "Apart from inclusion/exclusion, sometimes the need to start within a
certain period."
Regulatory barriers to trial activation (6) "Getting trials open - bureaucratic hoops."
Inability to identify eligible patients (4) "(…) it is difficult for a CRC to keep on top of all potentially eligible patients,"
Overwhelmed patients/families (3) "Physicians struggle with when to approach (…) when MDs choose to wait,
the studies are often forgotten."
Interests and priorities (13)
CCL not a priority (8) "(CCL is) at the bottom of our priority list amongst all other front line
treatment studies."
"Investigators focusing all their efforts on the treatment studies."
Lack of family interest (3) "Feeling like they will be taking another medication that is really not required."
Perceived negative effects of study medications (2) "Some physicians may be biased about perceived effects/side effects of
the study."
Resources (6)
Lack of adequate resources (4) "Studies that have research funded procedures (are easier)."
Low reimbursement (2) "Low reimbursement."
Abbreviation: CCL, Cancer Control and Supportive Care; COG, Children’s Oncology Group; CRA, Clinical research associate; IRB, Institutional review board; NP, Nurse
practitioner; CRC, Clinical research coordinator; MD, Medical doctor.
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role is important to successful trial implementation and
accrual [10]. These tasks include, but are not limited to
identification and enrollment of patients, collection of
samples and outcome data, tracking questionnaires, sub-
mitting adverse events, providing education to partici-
pants, and educating healthcare professionals on trial
conduct [13]. Identification of individuals responsible for
such tasks can improve enrolment rates considerably
[14]. The role of the CRA is particularly important since
clinicians are typically already working at maximal cap-
acity and cannot take on the extra administrative and
task burdens of clinical trial activities [8].
Survey responses suggest that staff presence and dy-
namics are key elements for institutional success in con-
ducting CCL research. Teams appear to be typically
composed of physicians, nurses, CRAs, pharmacists and
other healthcare professionals. As a way to address this
issue, we have proposed workshops where successful in-
stitutions that have created “CCL teams” present theirsystems to the membership and serve as role models
and resources for other institutions. For example, the
COG CCL Committee organized a well-attended session
at the Fall 2012 COG meeting and plan to continue to
hold similar sessions.
We also found that involvement of the physician ap-
pears to be important, at least for some study types.
Heiney et al. also identified that some studies rely upon
physician support depending on trial type [8]. The iden-
tification of a CCL champion was also highlighted as an
important issue. We define a CCL champion as a mem-
ber of the pediatric oncology clinical research team (may
be a physician, nurse, CRA or other team member) who
has a strong interest in, and commitment to CCL re-
search. He/she carries out several important functions
including ensuring CCL studies are activated by the in-
stitution in a timely fashion, developing systems for
identifying and screening potential subjects, and educat-
ing the patient, family and entire healthcare team about
CCL protocols. We have begun to address this issue in a
Table 3 Suggested approaches from COG and CCL that would facilitate accrual at the institutions
Themes and sub-themes (number of times mentioned) Example quotations
Staff presence and dynamics (2)
Awareness (2) "Encourage newer COG CRA and RN members to participate."
Logistics including adequate numbers of eligible patients (14)
Ensure study is feasible and minimize data collection (6) "Simplify, simplify, simplify! Distill CRFs down to the bare minimum
data needed to answer the study aims."
Email reminder for eligible patients (5) "It would be really helpful to have email alerts."
"Email reminders about patients who have been flagged as potentially
eligible can be helpful."
Broaden eligibility (3) "Keep requirements to a minimum."
"(…) more CCL trials for disease sites that do not currently have a
treatment trial."
Interests and priorities (2)
Patient potential benefit (1) "Data that shows outcomes of patients enrolled on CCL studies would
generate enthusiasm from staff."
Patient incentives (1) "Patients always like incentives for participation."
Resources (30)
Support from CCL committee (13) "I think the committee members/protocol staff members are extremely
responsive, supportive, and never leave us hanging."
Funding (12) "Increased per case reimbursement."
"Have it count as a therapeutic trial for payment/accrual."
Information provision (4) "CCL study sessions at COG Fall Meeting (…) was extremely helpful to
learn from what worked and what didn't work at other sites. It demystified
a lot of my apprehensions in opening the study at my institution."
"Have a meeting with all the lead CRAs and review protocols that are
available and ask for input."
Centralized CCL staff (1) "Provide a CCL centralized staff that do the regulatory for CCL protocols
remotely and abstract and submit the data either remotely or otherwise."
Abbreviation: CCL, Cancer Control and Supportive Care; COG, Children’s Oncology Group; CRA, Clinical research associate; RN, Registered nurse; CRF, Case
report forms.
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responsible individual for each site. This individual
would then act as the CCL champion and could repre-
sent the institution at meetings and when institutions
are polled for their enthusiasm regarding a potential
CCL study. We believe that identification of institutional
CCL champions is a particularly important step toward
enhancing accrual rates.
The CRAs in our sample noted that greater per-
case reimbursement and more “credit” for CCL en-
rollments would be beneficial. In COG, therapeutic
and CCL enrollments tend to provide the same reim-
bursement value. However, funding to travel to the
annual meeting is currently calculated based on thera-
peutic enrollments and CCL enrollments are not con-
sidered. If CCL enrollments are to be targeted, both
therapeutic and CCL trials should be considered in any
funding formula.
The CRAs also suggested a central CRA who can take
over some of the regulatory burdens from sites. Regula-
tory burdens appear to be increasing in spite of thepresence of the Central Institutional Review Board.
O’Mara et al. has previously described challenges to ac-
crual for NIH-funded research in the palliative care area
and noted that regulatory hurdles and patient accruals
were important limitations even among well-funded
studies [15]. Carter and colleagues also stressed the im-
portance of a central coordinator center to facilitate
study activation at individual centers and to problem-
solve issues quickly and efficiently [7].
The strengths of our study include soliciting the
opinions of the CRA membership, a group critical to
co-operative group trial conduct. This approach is
novel and these opinions are not well known. Further,
we obtained opinions from many institutions; this ap-
proach increases the generalizability of our findings.
However, our results must be interpreted in light of
its limitations. We did not survey sites with no CCL
accruals; these are institutions that may be facing the
greatest challenges to CCL accrual and may have
unique issues. Second, while we believe these com-
ments are generalizable to non-CCL non-therapeutic
Figure 1 Barriers and facilitators to accrual to CCL studies. Illustrates an overview of themes and sub-themes of barriers and facilitators to
accrual to CCL studies.
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generalizability to therapeutic trials or outside of the
pediatric setting is not assured. Finally, as a descriptive
study based on opinion only, the strength of evidence is
limited in our report.
Future research should focus on surveying institu-
tions who do not participate in CCL trials as these
responses will be particularly informative. The ideal
format for surveying these sites may differ and more
specifically, telephone contact may yield better response
rates since non-participation may reflect lack of interest
in CCL studies. Future studies may also consider a mixed
method design or include additional qualitative assess-
ment protocols to explore further the issue of non-
participation.
Conclusions
In summary, this study resulted in suggestions to facili-
tate CCL trials in the future. Many suggestions wereactionable including study designs which are feasible
and which avoid the initial diagnostic period, promo-
tion of CCL teams through role modeling, frequent
CRA education and lobbying to improve institutional
credit for each CCL enrollment. Some suggestions will
be more difficult to implement such as a central regula-
tory personnel. Soliciting input from key team members
in the clinical trials process is important to maximizing
accrual rates.Additional file
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